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This report describes the clinical improvement and acquisition of tuberculin skin-test 
sensitivity by a tuberculin-negative, drug-resistant patient with lupus vulgaris a fter a single 
injection of dialyzable transfer factor (TFd) from a tuberculin-positive healthy donor. The 
patient's lymphocytes showed a s light response to tuberculin in the le ukocyte migration 
inhibition test and in the lymphocyte transformation test before T Fd injection. T he 
acquisition of cellular immunity to tuberculin was demonstrated in vitro by enhanced 
tuberculin -induced blast t ransformation. A good correlation between skin test and in vitro 
tuberculin sensitivity and clinical improvement was seen during the three years that the 
patient was observed. 
Delayed hypersensitivity skin reactions to vari-
ous fungal, bacterial , and viral antigens can be 
obtained in previously nonreacting individuals 
after injection of dialyzable extracts of leukocytes 
from positively reacting donors (reviewed in [1 )) . 
This has been thought to represent positive .. trans-
fer .. of specific delayed hypersensitivity by a spe-
cial substance termed dialyzable transfer factor 
(TFd ) [1]. Thus. injections ofTFd have been given 
to patients with immunodeficiencies, chronic in-
fections. autoimmune diseases. and neoplasia [1 ]. 
In t his paper we describe the clinical course of a 
patient with drug-resistant, tuberculin-negative 
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lupus vulgaris following a s ingle inject ion of TFd 
from a healthy tuberculin-positive subject 
C'ASE HI. TORY 
The patient, a white male. first developed facial skin 
lesions at age .n. histologically diagnosed as lupus 
vulgaris at age 48. Pulmonary tuberculosis was diagnosed 
by chest x-ray findings also at age 48. The patient was 
con~istently on antituberculosis treatment. On the basis 
of the clinical diagnosis. before the diagnosis was histo-
logically confirmed. he receil'ed Isoniazid from age 45 for 
2.5 years, then Isoniazid and Ethionamid for 2.5 years; 
subsequently the treatment was changed to a combina-
t ion of Capreomycin. Rifampicin. and Ethambutol. This 
treatment lasted for I year and was continued during this 
study. No clinical improvement was observed during any 
of the above treatments. 
The patient was first seen at age 51 at the Department 
of Dermatology. University Central Hospital. Helsinki, in 
October 1971. On admission, an extens ive skin lesion was 
seen in the face. and the nose was almost totally 
destroyed (Fig.). Skin biopsy revealed morphologic 
changes consistent with active lupus vulgaris. A dest ruc-
t ive sinuitis was observed in both maxillae. and the 
diagnosis of tuberculosis was histologically confirmed by 
biop~y. The right index finger was greatly thickened, and 
the diagnosis of tuberculous osteitis was confirmed on the 
basis of x-ray findings. 
MATERIALS A:'\0 METHODS 
Skin tests. Skin tests performed by intradermal injec-
tion of 0.1 ml of each test antigen a nd saline control were 
read at 24 and 48 br after injection. Tbe antigens used 
were purified protein derivative of tuberculin (PPD, 
Statens Seruminstitut, Copenhagen). Candida albicans 
antigen (Dermatophytin "0", HolHster-Stier Laborato-
ries, U.S.A.). Kveim preparation Lot 131 (Finnish Kveim 
material ), and lepromin antigen . 
Preparation of TFd. TFd was prepared from a single 
healthy donor who had a strong pos itive ski n test to 0.1 
TV of PPD. Heparinized blood (450 ml) was collected 
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FIG. Facial views before (left) and 13 months after (right) a single dose of t ransfer factor . 
into a Fenwal bag, and the leukocytes were separated 
from red cells by sedimentation for 60 min at 37° C after 
addition of an equal volume of 6% dextran (Macrodex. 
Leiras Pharamaceutical Co., Turku, Finland). The 
supernatant (containing leukocytes) was centrifuged at 
1000 rpm for 20 min. The leukocytes were washed twice 
with PB , counted , and dissolved in 2 ml of pyrogen-free 
water. Cell lys is was achieved by freezing and thawing 10 
times. and the lysate was dialyzed against 200 ml of water 
for 24 hr. The dialysate was concentrated by lyophiliza. 
tion. dissolved in 20 ml of PB . and s terilized with 
Millipore filtration (pore sizes 0.22 .urn). In the final 
preparation I ml of TFd represented 0.9 >< JO" mononu· 
clear cells. 
Ly mphocyte cultures. The methods used a re described 
elsewhere [2]. After sedimentation of venous blood. the 
white blood cells (WBC'l were collected and washed. and 
the cell density was adjusted to 4 x 10' WBC per mi. 
Cultures of 2.5 ml were set up in 35-mm plastic Petri 
dishes with 80 'Y medium RPMI 1640 and 20"k the 
patient's own plasma. All cultures were set up in dupli· 
cate. Phytohemagglutinin (PHA-P. Difco) was used in a 
final dilution of I :250. PPD was used in a concentra tion 
of 10 .ug per mi. 
PHA-induced res ponse was measured on the third day 
and PPD· induced response on the s ixth day, which in our 
previous s tudies [2.3] were found to be the days of 
maximum responsiveness of lymphocytes to these stimu-
lants. In our experience, the percentage of blasts relative 
to lymphocytes is a more reliable method for measuring 
low blast responses than the amount of ["H TfdR incorpo-
ration into D A determined by liquid scintillation 
counting [3- 5 ]. T herefore, the results for PPD- and PHA-
stimulated cultures in the present study are given as the 
percentage of blasts . Cell preparations for May-Gruen-
wald- Giemsa (MGGl staining were made with a han-
don cytocentrifu!{e. For determination of the percentage 
of blasts, at least 100 blasts were scored or the blasts were 
counted on an a rea calculated to correspond to at least 
2000 lymphocytes. Percentages of blasts in PPD-
stimulated duplicate cultures did not differ by more than 
5 vt, . and those in PHA-stimulated duplicate cultures by 
not more than 7o/r . The percentages of blasts are given as 
means of the percentages of duplicate cultures. ln the 
presentation of the data for PHA· and PPD-induced 
lymphocyte transformation, the percentages of blas ts in 
control cultures without any stimulants have been sub-
tracted. 
Leukocyte migration inh1bition test. The leukocyte 
mi!!fation inhibition test [6 ] was used. Ten to 20 ml of 
hepa rinized blood (50 IU/ ml) was mixed with equal 
volumes of 6c:( dextran (Macrodex. Leiras Pharmaceuti-
cal Co., Turku. Finland) and kept at 37°C for 45 to 60 
min. The leukocyte-rich supernatant was collected, and 
the cells were washed twice with MEM and counted. Cell 
concentration was adjusted to 10" cells per ml of MEM 
with 10% newborn calf serum (Orion Pharmaceutical Co .. 
Helsinki. Finland). and the suspension was drawn into 
20-111 capillary tubes . The tubes were sealed with Seale 
Ease (Clay-Adams lnc., ew York. .Y.) and cen-
trifuged at 1000 rpm for 10 min. and then cut at the 
cell - liquid interface and placed into the chambers . ter-
ile. disposable leukocyte migration plates (Sterile-Limit-
ed. R ichmond. Surrey) were used. PPD at concentrations 
of 25 .ug per ml were used. Controls were without PPD. 
Migration was recorded with a photographic e nlarger 
after 18 hr at 37°C. and the migration index (MI) was 
calculated using the formula: 
MI " (meanarea of migrationwithantigen) x 100 
mean area of migration without antigen 
"Rosette" formation (enumeration of T-cells ). To 
determine the relative numbers of lymphocytes bearing 
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receptors for sheep red cells (SRC) (E-rosettes), the 
method of Jondal et a.l f7 ), slightly modified, was used 
[8]. In addition to the lymphocyte purification method, 
the main modification was counting of the E-rosettes in a 
hemocytometer after incubation overnight in t he cold. 
RESULTS 
Immunologic Findings before Injection of TFd 
Before the TFd injection the patient's skin 
reactions to 100 TU of PPD to 1:50 and 1:500 
dilutions of t richophytin were negative. K veim and 
lepromin tests were negative. He responded with a 
positive skin test to DermatophytiD "0'' at 1:50 
dilution. In vitro his cells showed a positive re-
sponse to PPD in the leukocyte migration inhibi-
tion test (MI = 47.2), and PPD induced a weak 
lymphocyte t ransformation in lymphocyte cultures 
(2.1 %) (Tab.). PHA-induced lymphocyte transfor-
mation was slightly decreased (Tab.), since in 18 
control subjects the percentage of blasts in PHA-
stimulated cultures was 65 ± 14 (mean ± 95% 
confidence limits). Immunoelectrophoresis re-
vealed normal l gG, C3, and lgM levels and poly-
clonal elevation in the IgA. The titer of antibodies 
to Epstein-Barr virus capsid antigens (VCA) was 
high (1:5120), compared with a geometric mean 
titer of 1:217 for anti-VCA antibodies in 25 con-
t rols. 
Clinical Course and Immunologic Status after TFd 
Injection 
In December 1971. 1 ml of TFd was injected in 
two 0.5-ml doses in the patient"s arm. PPD at a 
concentration of 100 TU was injected intrader-
mally at one site of TFd injection. and doses of 100 
T U and 10 TU were injected into the patient's 
thigh. The TFd alone did not cause any reaction. 
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At the site of the combined injection of TFd and 
100 TU of PPD, there was a redness and induration 
10 mm in diameter at 24 hr and 2 mm in diameter 
at 48 hr. Systemic sensitivity to tuberculin was 
observed in the leg at 24 hr as a redness and 
induration of 10 mm in diameter in response to 100 
TU of PPD; after 48 hr this reaction was 25 mm in 
diameter, and after 72 hr only redness was ob-
served. When retested 4 days after t he TFd injec-
tion, the skin test was sti ll positive to 100 TU and 
negative to 10 TU of PPD. Two months after the 
TFd injection the patient was positive even with 1 
TU of PPD (Tab.). He showed a positive skin 
reaction with 10 TU when tested 4.8 months and 
10.7 months after the TFd injection. Beginning 
13.4 months after the injection, a positive skin 
reaction was obtained only with 100 TU (but not 
with 10 TU) for 1 year. The firs t negative skin 
reaction with 100 TU was observed 2.7 years after 
the TFd injection. Due to activation of tuberculous 
skin lesions at t his time, antituberculosis treat-
ment with Rimactan and Ethambutol was started 
without any new TFd injections. Two months later 
the patient showed a positive skin test with 10 TU 
without any new TFd injection. This reactivity was 
still present 8 months later. 
Four days after TFd inject ion, reactivity to PPD 
in ,·itro had become negative, as measured by 
PPD-induced lymphocyte transformation (0%) 
and leukocyte migration inhibition (MI = 116) 
(Tab.). At 2 months. when the patient was positive 
to 1 TU in the skin test. the percentage of blasts 
in PPD-stimulated cultures was 22G't . and later it 
was 5.9 to ll o/c (Tab.l. In the leukocyte migration 
inhibit.ion test there was PPD-induced inhibition 
(Ml = 65) 4.8 months after the TFd injection. At 
this time the patient was posit ive to 10 TU in the 
TABLE. Effect of a single dose of transfer factor on M antoux sensitivity and in vitro ly mphocyte responses of the 
patient• 
Time after Mantoux 
Ly mphocyte tran~form ati(ln 
in \'It r<l ( .-; bfa~tl' 1• E-ro~eu es Mij!'ra t ton 
TFd tes t f (, tr indel(. 
PHA PPD 
- 1.5 mo IOOTU- 34a 4 ~a .I ;'\i'D 
0 lOOTU - 45 2. 1 47.2 
2 day!' lOOTU+ ND 2.8 ND 
4days lOOTU+ 19 0 116 
2.1 mo 1 TU+ 29 22 ND 
4.8mo IOTU+ 36 6.8 65 
10.7 mo lOTU+ 38 11 ND 
13.4 mo 100 l'U+ 32 6.8 77 ND 
2.1 yr 100TU+ 15 5.9 54 ND 
2.7 yr l OOTU- 20 ND 68 ND 
2.9 yr IO T U+ 29 31 77 10 
3.4 yr lOTU+ ND ND ND ND 
• Antituberculosis treatment was discontinued 2.0 years after the TFd injection and restarted 2.8 years after the 
injection. 
b The percentages of blasts in control cultures was less than 0 .2%. 
<£-rosettes in controls were 78.7 ± 7.8% (mean ± SD). 
a Percentages of blasts in control cultures have been subtracted. 
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skin test. When the antituberculosis treatment 
without any new TFd injection turned the negative 
skin test to pos itive, the patient showed a positive 
s kin test to 10 TV of PPD and the percentage of 
blasts in PPD-stimulated lymphocyte cultures in-
c reased to 31 0;( (Tab.). 
No increase in PHA-induced response after TFd 
injection was observed (Tab.). Rosette formation 
was studied 1 year after the TFd injection. The 
proportion of E -rosette-forming cells (E -RFC) was 
similar to that for normal controls (78.7C1 ± 7.8) 
(mean :r. SD). 
During the first 2 weeks after the TFd injection 
no changes were observed in the patient's clinical 
course. No fever or pain in the skin lesions was 
observed. A clinical improvement was noticed 2 
months after the TFd injection and was more 
pronounced 5 months after the injection. The 
intensive color and the induration with small 
nodules diminished on the borders of the facial 
s kin lesions (Fig.). imilarly. the contour of the 
index finger became closer to normal. Thirteen 
months after the TFd injection there was no 
evident active tuberculous process. and 11 months 
later the antituberculosis t reatment was discon-
tinued. Within 8 months after the end of the 
treatment. the borders of the skin lesions became 
indurated and mall nodules were palpable on the 
borders. At the . arne time the index finger of the 
patient was swollen. In chest x-rays no activation 
of pulmonary tuberculosis was observed . At this 
time the patient had become negative to 100 TU of 
PPD in the s kin te t. Because of the activation in 
the skin les ions the antituberculosis treatment 
with Rimactan and Ethambutol was sta rted. In 2 
months the intensive color of the lesions and the 
induration of their borders were diminished. The 
patient showed a positi\'e skin reaction with 10 Tu 
of PPD without any further injections of TFd . Six 
months later. when he was een for the last time at 
the Department of Dermatology. University Cen-
tral Hospital, Helsinki. no evident active tubercu-
lous process was observed on skin lesions or else-
where. and the skin test was st ill positi\'e with 10 
Tli of PPD. 
DISC'l'SSIO:'\ 
This report describes a tuberculin-negative 
patient with lupus vulgaris who showed gradual 
clinical improvement and acquisition of Mantoux 
sensitivity following one injection of TFd from a 
tuberculin-positive normal donor. M ycobacterium 
tuberculosis can be cultured from the skin lesions 
in 6% of patients with lupus vulgaris !9 ]. Though 
tubercle bacilli were never isolated in the present 
case. the clinical history as well as objective 
findings seem to verify the diagnosis of lupus 
vulgaris. The skin lesions of the patient were 
typical for this disorder. and their histology was 
consistent with the diagnos is. Furthermore, the 
chest x-ray findings, the histologically verified 
tuberculous sinuitis, and the radiologic picture of 
the bone lesion in the patient's finger all support 
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the diagnosis of widespread infection due to tuber-
cle bacilli. It might be that the negative bacterial 
cultures in this case were due to long-lasting 
bacteriostatic drug therapy. 
It has been reported that even monovalent 
treatment with Isoniazid for 19 months is sufficient 
in lupus vulgaris [10). Among 39 patients treated 
for 10 to 18 months, relapses occurred in two. All 
7 patients who had received Isoniazid treatment 
for more than 18 months showed permanent cure 
[1 0 ]. The present patient had received Isoniazid 
alone for 2.5 years and in combination v.rith Ethion-
amid for 2.5 year . and had received Capreomycin, 
Rifampic in. and Ethambutol for 1 year hPforp TFd 
therapy. Therefore, the cause of the patient 's un-
responsiveness to antituberculosis therap.\· appar-
ently was not in the choice of drugs but rather in 
the patient's immune response. The decrease in 
PHA-induced lymphocyte transformation suggests 
a slight general defect in T-cell function. Furthe r-
more. the patient ·s skin test with PPD was re-
peatedly negative even when high doses of PPD 
were used. The combination of lupus vulgaris to-
gether with a negative skin te t to PPD is an un-
common finding, as most of the cases with this 
disorder show a moderate or high skin sensitivi tv to 
PPD [11). :\o other ca e of lupus vulgaris negative 
to 100 TU of PPD was found in the records of 266 
patients in our clinic. 
ln spite of a negative skin test. tuberculin 
sensitivity of the patient's lymphocytes could be 
demonstrated in vitro by PPD-induced ly m-
phocyte transformation and by leukocyte migra-
tion inhibition tes ts. The dis ociation of s kin 
sensitivity. antigen-induced blast transformation, 
and production of migration inhibitory factor has 
been observed in many immunodeficiency states 
[1,3.12.13]. It is possible that delayed hypersensi-
t i\'ity. blastogene is in \'itro. and production of 
migration inhibition factor are res ponses mediated 
by functionally different populations of T -cells 
(14). 
The mechanism of action of transfer factor (TF) 
is not known. and e\'en the immunologic specificity 
of TF is not univer ally accepted. It is conceivable 
that. rather than recruiting pre\·iously uncommit-
ted cells, TF may have an enhancing effect on the 
reactivity of a previously committed clone of cells 
or may overcome suppression by excessive anti-
genic loads [15.16 ]. It has been s uggested that 
administration of exogenous TFd is followed in 
vivo by endogenous TF production from respond-
ing cells and that this in turn plays an important 
role in recruitment of nonimmune lymphocytes, 
thereby greatly enhancing the immune response 
[16 ]. The present patient ob\·iously had some 
tuberculin-sensitive cells that were able to react to 
PPD in vitro (T ab.). In addition. he probably also 
had large amounts of antigen in his body because 
of the widespread tuberculous infection. Thus, it 
appears that the TFd injection ' ' turned on" the few 
p reviously tuberculin-sensitive cells to recognize 
the antigen present. In in vitro studies it has been 
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shown that interaction of sensitized lymphocytes 
and antigen results in the liberation of the corre-
sponding TF from the sensitized lymphocytes [1, 
17]. Similarly, interaction of a few sensitive lym-
phocytes with the antigen in this patient could 
have started the production of endogenous TFd as 
well as lymphokines of various sorts. which then 
enhanced the immunologic responsiveness of t..he 
patient. That no tuberculin-induced blast trans-
formation or leukocyte migration inhibition was 
observed on the fourth day after TFd might be 
explained as desensitization of the few tuberculin-
sensitive cells by the large amount of antigen 
present. 
An alternative explanation for the negative 
results of in vitro tests on the fourth day is that if 
antigen-reactive cells were present, they were not 
detected in the peripheral circulation because of 
their sequestration in sites of active ini1ammation. 
Such sequestration of ant igen-reactive cells has 
been reported previously [18] and has also been 
seen after TFd therapy in lepromatous leprosy 
[19), in chronic mucocutaneous candidiasis (Hors-
manheimo. unpublished data). and some malig-
nant tumors [13]. However. no clinical symptoms 
(inflammation of the skin lesion, pain. or fever) 
were observed in the present case. 
There was no difference in t he proportion of 
E-RFC in this patient when he was skin-test 
negative to 100 TU or positive to 10 TU of PPD. 
Thus the T-cell deficiency presumably responsible 
for lack of skin sensitivity and response to conven-
tional therapy appears to be due to a qualitative 
defect in T-cells. not a reduction in their number . 
It is of interest that the dose of TFd used in this 
patient was rather low compared to t hose used in 
therapy of many other immune deficiencies. ln 
fact, the dose was similar to that used to transfer 
delayed hyper ensitivity in normal persons [1). 
The long duration of transferred skin sensitivity in 
the present patient seems also to be similar to the 
duration obtained in normal persons receiving TFd 
[1 ]. 
To exclude the possibility that the two skin tests 
with 100 T U of PPD before TFd injection could 
have an effect on the patient's reactivity, we 
repeatedly tested 10 out of 13 control patients 
negative to 100 TU of PPD (same patients as 
reported in [3]), a total of 8 times at 2- to 3-day 
intervals. None of the patients showed any skin 
reactivity after 4 tests. One patient showed a 
positive skin test to 100 TU of PPD after 5 tests, 
one after 6 tests, and one after 8 tests. None of 
these 3 patients showed reactivity to 10 TU of 
PPD. even when retested 0.5 to 1.5 years later. 
Therefore. the skin sensitivity and increase in 
PPD-induced lymphocyte transformat ion in t he 
present case is presumed to be due to the effect of 
TFd and not to the skin testing. 
When this patient became skin-test negative to 
100 TU of PPD, progression of tuberculous skin 
lesions was observed. T hese observations strongly 
suggest that the patient's lymphocytes were no 
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longer able to produce factors responsible for skin 
sensitivity and for the therapeutic effect, possibly 
because the production of endogenous TF had 
stopped. However. although he had shown no 
response to antituberculosis treatment for 6 years 
before TFd injection, conversion to positive skin 
test with 10 TU of PPD and clinical improvement 
were seen within 2 months after combined 
an tituberculosis treatment was restarted. with no 
new TFd. Therefore, it appears t hat the lym-
phocyte defect was only partial. and that t he 
lymphocytes were able to respond when excess 
antigen was eliminated [15). Return of delayed 
hypersensitivity after extensive treatment of 
mucocutaneous candidiasis without TFd has also 
been reported [20]. 
TFd has previously been applied to the therapy 
of 1 patient with disseminated tuberculosis who 
failed to respond to conventional treatment l21 ); 
however, repeated administrat ion of TFd and 
higher concentrations were needed for the remis-
sion of that tuberculin-negative patient with mili-
ary tuberculosi [21]. The findings in this case 
report suggest that , in some immunodeficiency 
patients, only one triggering injection of TFd may 
be needed to stimulate in vitro as well as in vivo 
immunologic responsiveness of lymphocytes to t he 
same level as in normal subjects for everal years. 
We thank Mrs. Hilkka Sokura for skillful technical 
assistance. and Charles L. Smith for editorial assistance 
with the manuscript. 
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